Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cemiplimab as Neoadjuvant Therapy in Cutaneous Squamous Cell Carcinoma
NCT04315701Phase 2Active, not recruiting
- Sponsor
- University of Southern California
- Start
- Jun 2020
- Primary completion
- Dec 2026
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of cemiplimab in cutaneous squamous cell carcinoma (cSCC), sponsored by University of Southern California. Started Jun 2020; status: active, not recruiting.
02
Drugs
cemiplimab
03
Conditions
cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on NCT04315701.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04315701.